{"id":13491,"date":"2010-12-06T09:30:00","date_gmt":"2010-12-06T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/nuove-ispezioni-antitrust-in-europa\/"},"modified":"2010-12-06T09:30:00","modified_gmt":"2010-12-06T08:30:00","slug":"nuove-ispezioni-antitrust-in-europa","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/nuove-ispezioni-antitrust-in-europa\/","title":{"rendered":"New antitrust inspections in Europe"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; line-height: normal; mso-layout-grid-align: none\"><span style=\"font-size: 12pt; color: #212120; font-family: BookAntiqua; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\"><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; line-height: normal; mso-layout-grid-align: none\" align=\"right\"><span style=\"font-size: 12pt; color: #212120; font-family: BookAntiqua; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\">&nbsp;<font color=\"#000000\"><font size=\"2\"><em><strong>Joaquin Almunia<\/strong> (President of the European Union Antitrust) <\/em><\/font><\/font><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; line-height: normal; mso-layout-grid-align: none\"><span style=\"font-size: 12pt; color: #212120; font-family: BookAntiqua; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\">The European Commission has announced that it has carried out new inspections in the offices of pharmaceutical companies that have allegedly delayed the market entry of generic medicines. Commission officials, accompanied by representatives of national competition authorities, say they carried out surprise inspections on the premises of &quot;a limited number of companies active in the pharmaceutical sector in several Member States&quot; on 30 November. In fact, the EU Commission thinks it has &quot;reason to think that the companies concerned have acted individually or jointly, in particular to delay the placing on the market of the equivalents of a particular drug&quot;. If this were confirmed, it would represent &quot;a potential breach of EU Antitrust law, which prohibits restrictive commercial practices and\/or the abuse of a dominant market position. Finally, the Commission noted that there is no legal deadline to complete investigations on anti-competitive behavior.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><em><span style=\"font-size: 9.5pt; color: #212120; line-height: 115%; font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; mso-bidi-font-weight: bold\">Barbara Di Chiara \u2013 Pharmakronos 6 December 2010<\/span><\/em><\/p>\n<p>&nbsp;<\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\" align=\"center\">\n<p><img loading=\"lazy\" decoding=\"async\" class=\"rg_hi\" id=\"rg_hi\" style=\"width: 259px; height: 194px\" height=\"194\" alt=\"\" width=\"259\" data-width=\"259\" data-height=\"194\" src=\"http:\/\/t2.gstatic.com\/images?q=tbn:ANd9GcQwcFVlYpCbY3V-8VaC8b5VqFpABTyfB6_1JXYkGpe4O9tkxzCg9w\" \/><\/p><\/p>","protected":false},"excerpt":{"rendered":"<p>&nbsp;Joaquin Almunia (Presidente dell&#8217;Antitrust dell&#8217;Unione Europea) La Commissione europea ha reso noto di aver effettuato nuove ispezioni negli uffici di aziende farmaceutiche che avrebbero ritardato l&#8217;ingresso sul mercato di medicinali generici. I funzionari della Commissione, accompagnati da rappresentanti delle autorit&agrave; nazionali garanti della concorrenza, affermano di aver effettuato accertamenti a sorpresa nei locali di &quot;un &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13491","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13491"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13491\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}